Biomira Inc. of Edmonton, Alberta, has completed the 60-dayreview of three investigational new drug submissions and isset to begin Phase II trials of Theratope in the treatment ofpatients with breast, colon and pancreatic cancer.

Theratope is designed to use proprietary. synthetic, cancer-associated antigens to stimulate a patient's own immunesystem.

The company said it would like to begin these trials in thefourth quarter of 1992.

(c) 1997 American Health Consultants. All rights reserved.